Intracellular Amyloid- in the Normal Rat Brain and Human Subjects and Its relevance for Alzheimer's Disease

Background: Amyloid-beta (A beta) is a normal product of neuronal activity, including that of the aggregation-prone A beta(42) variant that is thought to cause Alzheimer's disease (AD). Much knowledge about AD comes from studies of transgenic rodents expressing mutated human amyloid-beta protein precursor (A beta PP) to increase A beta production or the A beta(42/40) ratio. Yet, little is known about the normal expression of A beta(42) in rodent brains. Objective: To characterize the brain-wide expression of A beta(42) throughout the life span of outbred Wistar rats, and to relate these findings to brains of human subjects without neurological disease. Methods: A beta(42) immunolabeling of 12 Wistar rat brains (3-18 months of age) and brain sections from six human subjects aged 20-88 years. Results: In healthy Wistar rats, we find intracellular A beta(42) (iA beta(42)) in neurons throughout the brain at all ages, but levels vary greatly between brain regions. The highest levels are in neurons of entorhinal cortex layer II, alongside hippocampal neurons at the CA1/subiculum border. Concerning entorhinal cortex layer II, we find similarly high levels of iA beta(42) in the human subjects. Conclusion: Expression of iA beta(42) in healthy Wistar rats predominates in the same structures where iA beta accumulates and A beta plaques initially form in the much used, Wistar based McGill-R-Thy1-APP rat model for AD. The difference between wild-type Wistar rats and these AD model rats, with respect to A beta(42), is therefore quantitative rather that qualitative. This, taken together with our human results, indicate that the McGill rat model in fact models the underlying wild-type neuronal population-specific vulnerability to A beta(42) accumulation.